Bristol Who’s Who Recognizes Dr. Nicholas Sarlis, MD, PhD
Dr. Nicholas Sarlis, MD, PhD is the Vice President and Head of Medical Affairs at Incyte Corporation in Wilmington, Delaware. Dr. Sarlis is an experienced clinician, with knowledge of Hematology-Oncology, Experimental Pharmacology, Endocrine Neoplasia, Internal Medicine, Biostatistics and Data Analysis, Medical Affairs, Late Clinical Development, Health Outcomes and Pharmacoeconomics Research, Pharma-relevant regulations, guidelines, statutes and guidances and more.
Dr. Sarlis is in charge of establishing and strategically directing a multi-functional Medical Affairs team for the company’s lead program (ruxolitinib; formerly known as: INCB18424), as well as other compounds. He began his pharmaceutical career with Sanofi-Aventis (S-A) US, becoming Senior Medical Director and managing several parts of the S-A Oncology portfolio. Ruxolitinib was approved for use in the US (TM: Jakafi) on 16 Nov. 2011 for patients with intermediate or high-risk myelofibrosis. Dr. Sarlis currently supports all medical initiatives aiming at the successful commercialization of this brand in the US.
Dr. Sarlis has had extensive, superb medical training in both the UK and US in Internal Medicine, Molecular Biology, Endocrinology, and Endocrine Oncology. He has also had a decade-long academic career in the US. Dr. Sarlis served sequentially as Senior Clinical Investigator at the National Institute of Health, and as Associate Professor at the M. D. Anderson Cancer Center, the world’s largest cancer hospital. Through his latter attachment, as an endocrine malignancy key though leader himself, he forged lasting relationships with several leading oncologists in North America, Europe and the rest of the world. Over the last 14 years, he has focused on Oncology clinical & translational research on a global scale.
Dr. Sarlis’ skills include Senior Management/ Executive team/ CEO support, Departmental/ Divisional and Cross-Departmental Leadership, clinical trials design and operationalization, clinical & translational research portfolio management, complex data presentations and discussions, round-table & “cross-fire” panel coordination, innovative work-stream delineation and execution, life-cycle management scientific support, early product scientific support, company representation to external stakeholders; Advisory Boards and scientific debate fora leadership (pharma), and scientific data exchange programs leadership (pharma).
Dr. Sarlis’ abilities include timely and complete operational support for Executive team/ committee (ET/EC) members & CEO; scientific and medical support of Marketing and Commercial franchises and business units (pharma); timely and complete execution of tactical and operations plans (pharma); sensitivity to current and future (projected) market and science landscape (Oncology, pharma); expertise in scientific statements construction and conveyance (medical communications strategy & tactics); relationship management for consultants, agencies, vendors, clinical research organizations (CROs) at the leadership level; support of patient advocacy and education; and In-depth subject matter expertise through aggressive and continuous self-education, including attending of relevant conferences, scientific workshops and review of key journals and other medical and scientific literature.
Dr. Sarlis is an active member of the several learned societies focusing on cancer (ASCO, ESMO, ASTRO, AACR, ESO, SOHO, NYAS, AAAS), and regularly attends meetings of various organizations and consortia, such as NCCN, ASH, EHA, CSHL, MASCC/ISOO, WHO, ISPOR, HOPA, ASBMT, IBMTR, the European LeukemiaNet (ELN), and major US Coop Oncology Groups (e.g., ECOG, RTOG, ACOSOG, COG). He has been elected Fellow of the American College of Physicians, American College of Endocrinologists, Royal Society of Medicine (UK), Molecular Med Soc (US) and is the advisor for the Global Translational Medicine Consortium (GTMC), a member of the European Society for Translational Medicine (EUSTM) as well as a reviewer for the European Cooperation in Science and Technology (COST, under the auspices of the European Commission, EU).
Dr. Sarlis has received numerous awards for his activities. He has authored or co-authored 135+ peer-reviewed publications & book chapters with strong focus on cancer, and on medicines used in its treatment. Finally, Dr. Sarlis has delivered invited lectures and presentations in various fora worldwide – both in academic and industry settings.
Bristol Who’s Who VIP Member Dr. Nicholas Sarlis, MD, PhD can be found on the Who’s Who Directory where he is looking forward to networking with you.